MORGAN STANLEY PLC/CALL/MEDTRONIC/77.5/0.1/20.12.24 Share Price

Warrant

DE000MB9GEM7

Real-time Bid/Ask 16:37:20 26/06/2024 BST
0.57 EUR / 0.58 EUR -4.17% Intraday chart for MORGAN STANLEY PLC/CALL/MEDTRONIC/77.5/0.1/20.12.24
Current month-15.49%
1 month-21.05%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
26/06/24 0.61 +1.67%
25/06/24 0.6 -9.09%
24/06/24 0.66 -4.35%
21/06/24 0.69 +9.52%
20/06/24 0.63 +6.78%

Delayed Quote Börse Stuttgart

Last update June 26, 2024 at 01:08 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer Morgan Stanley
WKN MB9GEM
ISINDE000MB9GEM7
Date issued 04/08/2023
Strike 77.5 $
Maturity 20/12/2024 (177 Days)
Parity 10 : 1
Emission price 1.67
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.44
Lowest since issue 0.46
Spread 0.01
Spread %1.72%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
80.41 USD
Average target price
94.02 USD
Spread / Average Target
+16.93%
Consensus